Reconstitution of CD4+CD25highCD127low/-Tcell

NCT ID: NCT03736044

Last Updated: 2018-11-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-11-25
• Study Completion Date: 2017-03-13

Brief Summary

Rheumatoid arthritis (RA) is a systemic disabling inflammatory disease, of autoimmune origin characterized by chronic synovial inflammation resulting in joint damage. Treg cell function in patients with active RA is assumed to be impaired, a trend that seems to be reversed by TNFalpha antagonist therapy. Remission is the current treatment goal in RA.

An increasing number of patients in clinical trials achieve this goal raising the question whether patients who have been in remission for a prolonged period (sustained remission) still need medication indefinitely. From a decade TNF-blocker therapy have represented a new treatment option for RA patients non responders to conventional DMARDs and some evidence are now available showing that sustainable remission can be maintained achieved after withdrawal of TNF blocker. Objectives: to verify whether in RA patients in prolonged clinical and instrumental remission the percentages of CD4+CD25highCD127low/- T cells could represent a reliable marker of immunological remission and, even more relevant, if the pharmacological reconstitution of this "immune-modulator" Tcell population could contribute to better identify patients with a low risk of relapse after cessation of TNF-blocker therapy. Methods: in RA patients, who fulfilled the 1987 ACR revised criteria, with disease duration ! 5 years, clinical [Disease Activity Score on 28 joints-DAS28 0.56 ×√(TJC28) + 0.28×√(SJC28) + 0.70×ln(ESR) + 0.014×GH.TJC= Tender Joints Count (from 0 to 28); SJC= Swollen Joints Count (from 0 to 28) ESR=Erythrocyte Sedimentation Rate GH= patient's assessment of general health (VAS range from 0 to 100 mm); disease's flare was considered if: DAS44 >=2.4/DAS28 >=3.2.)], instrumental (joint ultrasonography: sites to be explored wrists are II-III metacarpophalangeal joint bilaterally using Power Doppler signal (grading 0-3); any other joint will be studied if symptomatic) and immunological (circulating CD4+CD25highCD127low/-Tcells and inflammatory cytokines levels) examination will be performed in order to asses, at different levels, disease activity status. Expected results: to identify in RA patients treated with anti-TNF an "exit-strategy" from these drugs based on clinical, imaging and immunologic features indicative of a sustained remission and to verify whether such conditions are able to predict a low incidence of relapse.

Detailed Description

1. To evaluate the incidence of disease flare after cessation of anti-TNF therapy in patients that meet sustained clinical and instrumental remission criteria together with reconstitution of the CD4+CD25highCD127low/- Tcell population respect to those patients in the same remission status with persistent low CD4+CD25highCD127low/- Tcell population.

2. Assessment of CD4+CD25highCD127low/- Tcell population behaviour induced by different drug treatments (anti-TNF vs DMARDs) in patient with RA who have achieved a prolonged remission status.

3. To assess the predictive value of modifications of CD4+CD25highCD127low/- Tcell population in patients who relapse.

Study design: all RA patients satisfying inclusion criteria will undergo to a baseline clinical, instrumental and immunologic evaluation. Peripheral CD4+CD25highCD127low/- Tcell population will be checked for and patients will be stratified in 2 groups:

• Group A: patients on treatment with TNF-blockers plus DMARDs
• Group B: patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF In addition a cohort of healthy subjects matched for sex and age will be used as a control.

Patient's blood samples will be centralized at the "Laboratories of Technology for Advanced Therapies" of the University of Ferrara (www.ltta.tecnopoloferrara.it) directed by Prof. Paola Secchiero.

In group A anti-TNF drugs will be withdrawn and patients will be followed up. Patients belonging to the group B will be followed up without any further intervention. A tight clinical monitoring will be instituted and disease flares-up will be recorded. In case of disease flare therapeutic adjustment will be provided to the patients by the attending specialist team accordingly to the current standard of care.

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

TNF-blockers withdrawal

Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.

Group Type: EXPERIMENTAL

TNF-blockers suspension in patients with rheumatoid arthritis

Intervention Type: DRUG

in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.

DMARDs control group

Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

TNF-blockers suspension in patients with rheumatoid arthritis

in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• patients with RA fulfilling the 1987 ACR classification criteria (10) treated with anti-TNF and/or conventional DMARDs for at least 12 months, in prolonged remission (DAS28 <2.6 or DAS44 <1.6) for at least 6 months (checked in two consecutive visits 3 months apart), without Glucocorticosteroid (for at least 3 months, before), on a stable treatment for at least 3 months.

Exclusion Criteria

• assumption of glucocorticosteroids within the three months before; confounding comorbidities such as fibromyalgia; chronic inflammatory disease other than RA; ongoing infections at the time of enrolment; recent trauma.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital of Ferrara

OTHER

Sponsor Role: lead

Responsible Party

Andrea Lo Monaco

Rheumatology Physician assistant/Principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

PRUa1GR-2013 -00000156

Identifier Type: -

Identifier Source: org_study_id